NOVAMINE 8.5%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVAMINE 8.5% (NOVAMINE 8.5%).
Novamine 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in patients who cannot obtain adequate nutrition enterally.
| Metabolism | Amino acids are metabolized via transamination, deamination, and urea cycle pathways in the liver and other tissues. |
| Excretion | Renal: >95% as amino acids and metabolites. Biliary/fecal: <5%. |
| Half-life | Variable; amino acids have short t1/2 of minutes to hours. Clinical context: continuous infusion maintains steady state; elimination depends on metabolic demand and organ function. |
| Protein binding | Minimal (<10%). Binding to albumin varies per amino acid. |
| Volume of Distribution | Vd ~0.3-0.5 L/kg, reflecting distribution into total body water and lean tissue. |
| Bioavailability | IV: 100%. |
| Onset of Action | IV: Immediate upon infusion initiation (15-30 min to reach steady state). |
| Duration of Action | Duration matches infusion; metabolic effects persist for hours after discontinuation. Clinical note: continuous infusion required for sustained effect. |
500 mL to 2000 mL intravenously per 24 hours, typically infused at a rate of 20 to 40 mL/hour; adjust based on metabolic and clinical response.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR < 30 mL/min) due to risk of hypervolemia and uremia; for GFR 30-50 mL/min, reduce dose by 50% and monitor BUN and creatinine; for GFR > 50 mL/min, no adjustment required. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25% and monitor ammonia levels; Child-Pugh Class C: contraindicated due to risk of hepatic encephalopathy. |
| Pediatric use | Neonates and infants: 2-3 g amino acids/kg/day intravenously; Children: 1.5-2 g amino acids/kg/day intravenously; adjust infusion rate to avoid exceeding glucose tolerance. |
| Geriatric use | Use lower end of adult dosing range (500-1000 mL per 24 hours) due to decreased renal and hepatic function; monitor fluid balance and serum electrolytes closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVAMINE 8.5% (NOVAMINE 8.5%).
| Breastfeeding | There are no adequate human data on the excretion of Novamine 8.5% into breast milk. The M/P ratio is unknown. The components are endogenous substances normally found in breast milk. Caution should be exercised when administered to nursing mothers. |
| Teratogenic Risk | Amino acid solutions like Novamine 8.5% are considered essential for maternal nutrition in pregnancy. No teratogenic effects have been reported in animal studies. Pregnancy exposure data are lacking; however, nutritional support is generally considered low risk. Use in pregnancy only if clearly needed. |
■ FDA Black Box Warning
Not for use in infants or children with metabolic disorders involving amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria). Risk of metabolic acidosis in patients with renal insufficiency or hepatic failure.
| Common Effects | Dizziness Sleepiness Tiredness Uncoordinated body movements |
| Serious Effects |
["Hypersensitivity to any component","Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria)","Severe liver disease with hepatic coma","Severe renal failure with uremia not undergoing dialysis"]
| Precautions | ["Monitor serum electrolytes, blood glucose, and acid-base balance regularly","Risk of hyperglycemia, hyperosmolar state, and fluid overload in patients with renal or cardiac impairment","Use with caution in patients with hepatic or renal failure as may worsen azotemia or encephalopathy","Thiamine deficiency may occur if dextrose is co-administered without adequate vitamins"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal serum electrolytes, acid-base balance, plasma ammonia, blood urea nitrogen (BUN), glucose, liver and renal function, and fluid balance. Monitor fetal growth and well-being via ultrasound if prolonged use. Assess for signs of fluid overload or metabolic abnormalities. |
| Fertility Effects | No specific effects on fertility have been reported with Novamine 8.5%. As a nutritional supplement, it is unlikely to adversely affect fertility; however, no formal studies have been conducted. |